– USA, MA – Seaport Therapeutics, a biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Dr.David Wheadon (M.D.) to its Board of Directors.
“I had the privilege of working with David on the Karuna board, so I know how incredibly fortunate we are to gain his unparalleled level of expertise and industry perspective at Seaport,” said Steve Paul, M.D., Founder and Chair of the Board of Directors at Seaport. “He has an accomplished career and an astute understanding of the regulatory and clinical landscape, which will make him a valuable addition to Seaport as we continue to advance our novel neuropsychiatric medicines through clinical development.”
About Dr.David Wheadon
Dr.David Wheadon is a physician and psychiatrist with more than three decades of experience in regulatory affairs, clinical strategy, and global health policy at multinational companies across the pharmaceutical industry. He is a distinguished pharmaceutical leader who most recently served as SVP of Global Regulatory Affairs, Patient Safety, and Quality Assurance at AstraZeneca. While at AstraZeneca, he drove regulatory strategy for the development and approval of the company’s product portfolio and oversaw the global regulatory affairs, patient safety, and quality assurance organization.
Dr. Wheadon also served as a member of the company’s Global Medicines Development Leadership team and Late-Stage Product Committee, which was responsible for the progression of AstraZeneca’s late-stage portfolio through clinical development, regulatory approvals, and market access.
“I’m excited to join the talented members of Seaport’s Board and executive team with deep experience and a proven track record of developing neuropsychiatric drugs,” said Dr. Wheadon. “Seaport has a promising pipeline of novel antidepressants and anxiolytics, and I look forward to being a part of the journey of delivering these important new treatments to the millions of patients suffering from devastating and debilitating mental health conditions, including depression and anxiety.”
Dr. Wheadon held previous leadership positions at the Pharmaceutical Research and Manufacturers of America (PhRMA), and the Juvenile Diabetes Research Foundation as well as senior regulatory and clinical development leader roles at Abbott and GlaxoSmithKline. He also served on the Board of Directors at Karuna Therapeutics until its acquisition by Bristol Myers Squibb in March 2024. He began his career as a clinical research physician in neuroscience at Eli Lilly. Dr. Wheadon earned an A.B. from Harvard College and an M.D. from Johns Hopkins University School of Medicine. His residency was in psychiatry at the Tufts-New England Medical Center. He is a member of the American Academy of Pharmaceutical Physicians and the American Psychiatric Association.
About Seaport Therapeutics
Seaport Therapeutics, a Founded Entity of PureTech Health plc (Nasdaq: PRTC / LON: PRTC), is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations overcome with its proprietary Glyph technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism, and reduce hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians, and key opinion leaders.
For more: https://seaporttx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.